Cohance Lifesciences Limited vs Blue Jet Healthcare Limited
Last updated: 28 October 2026
Cohance Lifesciences vs. Blue Jet Healthcare: A MoneyDock Comparison
MoneyDock brings you a comparative analysis of two prominent players in the Indian healthcare and specialty chemicals sector: Cohance Lifesciences Limited (COHANCE.NS) and Blue Jet Healthcare Limited (BLUEJET.NS). While specific detailed business descriptions are not provided in the given data, both companies operate within industries that are crucial to pharmaceuticals, nutraceuticals, and other related segments. Investors often compare them due to their similar market cap (implied as both are listed entities) and presence in complementary or competitive spheres within the broader healthcare ecosystem, making an evaluation of their performance metrics essential for potential investment decisions.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences Limited | Blue Jet Healthcare Limited |
|---|---|---|
| Current Price | ₹479.25 | ₹495.55 |
| 52-Week High | ₹539.85 | ₹626.25 |
| 52-Week Low | ₹279.90 | ₹327.25 |
| 1-Year Return | -10.99% | -6.73% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: With both companies having a 'N/A' for Trailing P/E and Market Cap, a direct comparison on traditional valuation metrics is not possible based on the provided data. Investors would typically need these figures to assess if a stock is overvalued or undervalued relative to its earnings and size. Without this, the current prices alone don't offer enough insight into their respective valuations.
Returns: Both Cohance Lifesciences and Blue Jet Healthcare have delivered negative 1-year returns, indicating a challenging period for both stocks. Blue Jet Healthcare, however, has performed relatively better, with a -6.73% return compared to Cohance Lifesciences' -10.99%. This suggests that while both are facing headwinds, Blue Jet Healthcare has experienced a slightly lesser decline in value over the past year. This could be due to better operational performance, market sentiment, or sector-specific factors affecting Cohance Lifesciences more severely.
Stability: To gauge stability, we can look at the current price relative to their 52-week highs and lows. Cohance Lifesciences is trading at ₹479.25, which is closer to its 52-week high of ₹539.85 than its low of ₹279.90. This indicates some recovery from its annual low or that it has sustained levels closer to its peak for a good portion of the year. Blue Jet Healthcare, at ₹495.55, is also closer to its 52-week high of ₹626.25 than its low of ₹327.25. While both are off their highs, Blue Jet Healthcare has a larger spread between its 52-week high and low (₹299) compared to Cohance Lifesciences (₹259.95), suggesting potentially higher volatility or larger swings in its stock price over the past year. Blue Jet Healthcare's current price is approximately 79% of its 52-week high, while Cohance Lifesciences' current price is approximately 88% of its 52-week high. This indicates that Cohance Lifesciences is currently trading closer to its yearly peak compared to Blue Jet Healthcare, which might imply slightly better recent price retention or less downside from its peak. However, both are well above their 52-week lows, indicating that they haven't capitulated completely.
Without Market Cap, Trailing P/E, and specific business insights, making a definitive call on which company is 'more stable' is challenging. However, based purely on the 1-year return, Blue Jet Healthcare has shown marginally better price resilience.
MoneyDock Verdict
Aggressive Investors: Given the negative 1-year returns for both, aggressive investors might see opportunities in these dips, but with a lack of P/E and Market Cap data, fundamental valuation is elusive. Blue Jet Healthcare, with its slightly better 1-year return, might present a marginally less risky 'dip buy' for those betting on a turnaround in the sector.
Conservative Investors: Both companies exhibit negative returns over the past year, which typically signals caution for conservative investors. The absence of fundamental valuation metrics like P/E ratio makes a thorough risk assessment difficult. Conservative investors might prefer to wait for more comprehensive data and a clearer uptrend before considering an investment in either company.
Long-Term SIP Investors: For long-term SIP (Systematic Investment Plan) investors, the current prices well below 52-week highs could be seen as accumulation points. Blue Jet Healthcare's comparatively smaller negative 1-year return might indicate a stronger underlying business or better market perception over the recent past, making it a potentially preferred choice for rupee-cost averaging, assuming a positive long-term outlook for the sector.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.